"Patients diagnosed with headache may benefit from concurrent behavioral health evaluation and treatment," researchers said.

The ACP issued new clinical guidance on preventing episodic migraines, classified as one to 14 headache days per month, in ...

The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.